Januari 2012
30
Koch R, Trefz F, and Waisbren S. 2010. Psychosocial issues and outcomes in maternal PKU. Mol
Genet Metab 99 Suppl 1:S68-74.:S68-S74.
Lee P, Treacy EP, Crombez E, Wasserstein M, Waber L, Wolff J, Wendel U, Dorenbaum A, Bebchuk
J, Christ-Schmidt H, Seashore M, Giovannini M, Burton BK, and Morris AA. 2008. Safety and efficacy
of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J
Med Genet A 146A:2851-2859.
Levy HL, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FK, Whitley CB, Feillet F, Feigenbaum
AS, Bebchuk JD, Christ-Schmidt H, and Dorenbaum A. 2007. Efficacy of sapropterin dihydrochloride
(
tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with
phenylketonuria: a phase III randomised placebo-controlled study. Lancet 370:504-510.
Loeber JG. 2007. Neonatal screening in Europe; the situation in 2004. J Inherit Metab Dis 30:430-
438.
Maillot F, Lilburn M, Baudin J, Morley DW, and Lee PJ. 2008. Factors influencing outcomes in the
offspring of mothers with phenylketonuria during pregnancy: the importance of variation in
maternal blood phenylalanine. Am J Clin Nutr 88:700-705.
Modan-Moses D, Vered I, Schwartz G, Anikster Y, Abraham S, Segev R, and Efrati O. 2007. Peak
bone mass in patients with phenylketonuria. J Inherit Metab Dis 30:202-208.
Moyle JJ, Fox AM, Arthur M, Bynevelt M, and Burnett JR. 2007. Meta-analysis of
neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol Rev 17:91-101.
Musson DG, Kramer WG, Foehr ED, Bieberdorf FA, Hornfeldt CS, Kim SS, and Dorenbaum A. 2010.
Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets
and the effects of food: a randomized, open-label, crossover study in healthy adults. Clin Ther
32:338-346.
Pietz J, Fatkenheuer B, Burgard P, Armbruster M, Esser G, and Schmidt H. 1997. Psychiatric
disorders in adult patients with early-treated phenylketonuria. Pediatrics 99:345-350.
Poustie VJ, and Wildgoose J. 2010. Dietary interventions for phenylketonuria. Cochrane Database
Syst RevCD001304.
Rouse B, Azen C, Koch R, Matalon R, Hanley W, de la Cruz F, Trefz F, Friedman E, and Shifrin H.
1997.
Maternal Phenylketonuria Collaborative Study (MPKUCS) offspring: facial anomalies,
malformations, and early neurological sequelae. Am J Med Genet 69:89-95.
Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, and de SL. 1994. Sustained attention in adult
phenylketonuria: the influence of the concurrent phenylalanine-blood-level. J Clin Exp
Neuropsychol 16:681-688.
Scriver CR, Levy H, and Donlon J. 2011. Hyperphenylalaninemia: Phenylalanine Hydroxylase
Deficiency. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, editors.
The Online Metabolic and Molecular Bases of Inherited Diseases .
Simon E, Schwarz M, Roos J, Dragano N, Geraedts M, Siegrist J, Kamp G, and Wendel U. 2008.
Evaluation of quality of life and description of the sociodemographic state in adolescent and young
adult patients with phenylketonuria (PKU). Health Qual Life Outcomes 6:25.